Xiidra (lifitegrast) treats dry eye disease by blocking a specific protein interaction that drives inflammation on the surface of your eye. It works differently from artificial tears, which only temporarily lubricate, and differently from cyclosporine (Restasis), which suppresses immune cells through a separate pathway. Xiidra is the first drug designed to target the interaction between two proteins, called LFA-1 and ICAM-1, that immune cells rely on to latch onto tissue and trigger inflammation.
The Protein Interaction Xiidra Blocks
Dry eye disease isn’t just about insufficient tears. In many people, it involves a self-reinforcing cycle of inflammation. Immune cells called T cells travel to the surface of the eye, attach to the tissue there, become activated, and release inflammatory signals that damage the tear-producing glands and the eye’s surface. This damage attracts even more immune cells, and the cycle continues.
The attachment step is where Xiidra intervenes. T cells have a surface protein called LFA-1, and the cells lining your eye’s surface and blood vessels display a matching protein called ICAM-1. When LFA-1 locks onto ICAM-1, it does two things: it lets T cells physically grip the tissue (so they can migrate out of blood vessels and into the eye’s surface), and it helps activate those T cells once they arrive. Activated T cells then release a cascade of inflammatory molecules, including several that are consistently elevated in dry eye disease.
Lifitegrast is shaped to mimic the part of ICAM-1 that LFA-1 normally binds to. It acts as a molecular decoy, fitting into the binding site on LFA-1 and preventing the real ICAM-1 from connecting. This is a direct competitive block: lifitegrast physically occupies the spot, so the immune cell can’t grab onto the tissue.
What Happens Downstream
By blocking that initial handshake between LFA-1 and ICAM-1, Xiidra disrupts multiple steps in the inflammatory process at once. T cells are less able to exit blood vessels and migrate into the eye’s surface tissue. Those that do arrive are less likely to become fully activated, because LFA-1/ICAM-1 binding is part of the “immunological synapse,” a structured connection between a T cell and the cell presenting it with an immune signal. Without that connection stabilizing the interaction, T cell activation is weakened.
Lab studies have shown that lifitegrast reduces T cell secretion of a broad range of inflammatory molecules, including ones involved in recruiting additional immune cells, amplifying inflammation, and directly damaging tissue. This is important because dry eye inflammation is not driven by a single molecule but by a web of signals reinforcing each other. By cutting off the activation step, Xiidra reduces the output of many of these signals simultaneously rather than targeting just one.
How It Compares to Cyclosporine (Restasis)
Cyclosporine, the active ingredient in Restasis, also targets T cell-driven inflammation, but through a completely different mechanism. Cyclosporine enters T cells and blocks an internal enzyme called calcineurin. This prevents the cell from turning on the genes that produce inflammatory molecules. It works inside the cell, after activation has already begun.
Xiidra works outside the cell, at the point of contact. It prevents T cells from attaching and becoming activated in the first place. In practice, this means the two drugs interrupt the same inflammatory cycle at different points. Some treatment guidelines position Xiidra as an option when cyclosporine hasn’t provided enough relief, or when patients can’t tolerate it. The VA health system, for example, lists Xiidra for patients who haven’t responded adequately to artificial tears and cyclosporine, or who have documented corneal surface damage despite using both.
What to Expect When Using It
The standard dose is one drop in each eye twice daily, spaced roughly 12 hours apart. Each dose comes in a single-use container that you discard after application. Some people notice symptom improvement in as little as two weeks, though broader improvements in both signs and symptoms are more typical at the 6- to 12-week mark. This delay makes sense given the mechanism: Xiidra isn’t lubricating the eye directly but rather dampening the inflammatory process that’s undermining your tear film. That takes time.
The most commonly reported side effects are a metallic or unusual taste in the mouth shortly after putting in the drops (the liquid can drain through the tear ducts into the nasal passages and throat) and mild irritation at the application site. Both tend to be temporary and short-lived. In a real-world study of 600 patients, about 85% were still using lifitegrast at the 12-month mark. Among those who stopped, the most common reasons were insufficient response (about 45%), intolerance to side effects (33%), personal preference (29%), and insurance coverage issues (24%).
Why the Mechanism Matters for You
Understanding that Xiidra targets inflammation rather than tear production helps set realistic expectations. If your dry eye is primarily inflammatory, meaning your eyes are red, gritty, or burning in a way that artificial tears only briefly relieve, Xiidra addresses the underlying process rather than just the surface symptoms. It won’t increase tear volume the way some other treatments aim to, but by reducing the immune activity damaging your eye’s surface, it can allow the tear film to stabilize and symptoms to improve over weeks.
If your dry eye is mostly from reduced tear production without much inflammation (common in older adults or after certain surgeries), the anti-inflammatory mechanism may be less relevant to your situation. This is one reason responses vary and why some patients find it effective quickly while others see limited benefit.